Key result
Elevated troponin in PSVT linked to ~8-fold higher odds of admission, but not 30-day major cardiovascular events.
Why the study?
Cardiac troponin testing is frequently performed in emergency department patients with paroxysmal supraventricular tachycardia, yet whether its influence on clinical decision-making is proportionate to its prognostic yield remained unclear.
Does cardiac troponin elevation predict hospital admission and 30-day major adverse cardiac events in emergency department patients with paroxysmal supraventricular tachycardia?
Cohort (n=360)
Yes
Does cardiac troponin elevation predict hospital admission and 30-day major adverse cardiac events in emergency department patients with paroxysmal supraventricular tachycardia?
In emergency department patients with paroxysmal supraventricular tachycardia, cardiac troponin elevation strongly drives hospital admission despite having poor predictive value and no independent association with 30-day major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
Troponin elevation should not drive admission decisions in PSVT; leaves open its value for 30-day MACE prediction.
Background Cardiac troponin testing is frequently performed in emergency department (ED) patients with paroxysmal supraventricular tachycardia (PSVT), yet whether its influence on clinical decision-making is proportionate to its prognostic yield remains unclear. Methods We conducted a multicentre retrospective cohort study across five branches of Taipei City Hospital (2016–2022). Of 611 initially identified encounters, 540 met inclusion criteria for chart-confirmed PSVT; 447 underwent troponin testing (124 troponin-positive and 323 troponin-negative). Variable-ratio propensity matching (sex exact, age ±2 years) yielded a matched cohort of 360 encounters. Primary outcomes were hospital admission and 30-day major adverse cardiac events (MACE), analysed by conditional logistic regression and receiver operating characteristic (ROC) analysis. Results Troponin elevation was strongly associated with hospital admission (adjusted OR 7.95, 95% CI 2.81 to 22.54; p<0.001) and stable to mean arterial pressure adjustment. It was not independently associated with 30-day MACE (adjusted OR 2.05, 95% CI 0.66 to 6.41; p=0.217; 18 events). Troponin alone demonstrated moderate discrimination for admission (area under the curve (AUC) 0.727, 95% CI 0.646 to 0.802) but limited and statistically uncertain discrimination for MACE (AUC 0.575, 95% CI 0.460 to 0.687; positive predictive value (PPV, 6.5%). A multivariable clinical model improved MACE discrimination (AUC 0.772, 95% CI 0.701 to 0.877). Conclusions Troponin elevation was strongly associated with hospital admission yet demonstrated limited discriminatory performance for 30-day MACE. This discordance, combined with a MACE PPV of 6.5% and evidence that clinical context substantially improves risk stratification, suggests that troponin results alone may not sufficiently inform disposition decisions in ED PSVT. Prospective studies defining a calibrated, clinically guided testing strategy are needed.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) conducted a cohort in Paroxysmal supraventricular tachycardia (PSVT) (n=360). Troponin elevation (troponin-positive) vs. Troponin-negative was evaluated on Hospital admission and 30-day major adverse cardiac events (MACE) (OR 7.95, 95% CI 2.81-22.54, p=<0.001). Troponin elevation strongly predicted hospital admission but not 30-day major cardiovascular events in ED patients with PSVT.
Synapse has enriched 10 related papers. Consider them for comparative context: